Subhanu Saxena

Cipla Q1 profit down 44%, US biz drags revenue; MD to step down

Cipla said its MD & Global CEO Subhanu Saxena has stepped down effective August 31 and MK Hamied shall continue to hold position of non-executive vice chairman.

Cipla launches generic hepatitis C drug in India

Cipla MD and Global Chief Executive Officer Subhanu Saxena said, "The launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus."

Cipla to pay for InvaGen, Exelan mostly through own funds

Cipla Global Chief Executive Officer Subhanu Saxena said both acquisitions would add to Cipla's earnings from Day One, and that the acquisition would give the company a strong platform to accelerate growth in US.

Cipla to acquire two US pharma companies for $550 mn

"Cipla today announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc, and Exelan Pharmaceuticals Inc," said the Mumbai-based pharma company in its filing.

Aiming to achieve 70-80% organic growth: Cipla

The pharma major's MD and CEO Subhanu Saxena says the company is aiming at achieving a growth of 70-80 percent growth without making any major acquisitions in the near future.

Cipla falls 5% on fears of Nexium sales slowdown post Q1

Higher profitability was a result of overall topline growth and leverage on cost base, said Subhanu Saxena, MD & CEO in an interview with CNBC-TV18. However, Esomeprazole sales impact will taper off in balance of this fiscal, he added.

Cipla sees senior, mid-mgmt level exodus in last 3-4 months

The most prominent name in the mass exodus is that of its CFO Rajesh Garg, who quit to pursue his entrepreneurial ambitions. Company CEO Subhanu Saxena is overseeing finance functions in the interim.

Cipla to sharpen focus on emerging markets in growth push

More than a decade after it made headlines globally for offering to make AIDS drugs for under USD 1 a day, Cipla gets nearly half of its sales from India, unlike most of its domestic rivals for whom the US market makes up the bulk of revenues.

Cipla gets USFDA nod for Lopinavir, Ritonavir oral pellets

The approval by the United States Food and Drug Administration (USFDA) is for an innovative formulation â€” Lopinavir/Ritonavir 40mg/ 10 mg oral pellets, Cipla said in a statement.

Cipla to launch generic Hepatitis C drug 'Hepcvir' in India

The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries, Cipla said.

Cipla awarded $188.95mn tender by Global Fund for ARV drugs

Cipla has been selected as a panel supplier under a supplier partnership agreement. The contract is effective from the January 1, 2015 and will run for a period of three years.

Cipla forms JV in Morocco to expand position in African mkt

Cipla forms JV in Morocco to enhance position in African mkt

Discussing partnerships, have done in-licensing deals:Cipla

The company's CEO, Subhanu Saxena, in an exclusive conversation with CNBC-TV18's Archana Shukla says the focus is on building the company for the long term.

Respiratory business expected to double in future: Cipla

Cipla CEO Subhanu Saxena in a conversation with CNBC-TV18's Archana Shukla said the respiratory business has immense potential for the company.

Cipla appoints Sameer Goel as India Head

Goel, in his last assignment, led a USD 0.4 billion business based out of Johannesburg, with responsibility for 44 markets in Sub-Saharan Africa. In his last India-based role at GSK, he led the sales team comprising 4,500 direct and indirect field executives.

Cipla acquires Croatia-based Celeris

Commenting on the development, Cipla MD & Global CEO Subhanu Saxena said: "Following our ambition to front end and establish a platform to market our own products, Celeris represented an opportunity for a ready-made platform, especially for our respiratory launches in Europe."

H1 inline; Cipla Medpro fully integrated: Cipla MD

Cipla MD & Global CEO Subhanu Saxena says he had signaled that the first 12-18 months in its roadmap was investing in the business for the future - particularly on people and also the pipeline to get in a position where it'll have sustainable platform for growth for the decade and beyond.